Journal
Molecular Cancer Therapeutics, 2020
Authors
James T. Topham, Emma Titmuss, Erin D Pleasance, Laura M Williamson, Joanna M Karasinska, Luka Culibrk, Michael Kuan-Ching Lee, Shehara Mendis, Robert E Denroche, Gun-Ho Jang, Steve E Kalloger, Hui-Li Wong, Richard A Moore, Andrew J. Mungall, Grainne M O'Kane, Jennifer J. Knox, Steven Gallinger, Jonathan M Loree, Dixie L Mager, Janessa Laskin, Marco A. Marra, Steven JM Jones, David F Schaeffer and Daniel J Renouf

Next-generation sequencing of solid tumors has revealed variable signatures of immunogenicity across tumors, but underlying molecular characteristics driving such variation are not fully understood. While expression of endogenous retrovirus (ERV)-containing transcripts can provide a source of tumor-specific neoantigen in some cancer models, associations between ERV levels and immunogenicity across different types of metastatic cancer are not well established. We performed bioinformatics analysis of genomic, transcriptomic and clinical data across an integrated cohort of 199 metastatic breast, colorectal and pancreatic ductal adenocarcinoma (PDAC) patient tumors. Within each cancer type, we identified a subgroup of viral mimicry tumors in which increased ERV levels were coupled with transcriptional signatures of autonomous antiviral response and immunogenicity. In addition, viral mimicry colorectal and pancreatic tumors showed increased expression of DNA demethylation gene TET2. Taken together, these data demonstrate the existence of an ERV-associated viral mimicry phenotype across three distinct metastatic cancer types, while indicating links between ERV abundance, epigenetic dysregulation and immunogenicity.

Back to top